Zoltan Vajo1, Gergely Balaton1, Peter Vajo2, Laszlo Kalabay1, Adam Erdman3, Peter Torzsa1. 1. Department of Family Practice, Semmelweis University, Budapest, Hungary. 2. Medical and Health Sciences Centre, University of Debrecen, Debrecen, Hungary. 3. Arizona State University, Tempe, AZ, USA.
Abstract
AIMS: The currently licensed seasonal trivalent influenza vaccines contain 15 μg haemagglutinin per strain for adult, and up to 60 μg for elderly patients. However, due to recent shortages, dose sparing to increase production capacity would be highly desirable. In the present study, we attempted to find a dose-response relationship for immunogenicity and, thus, the optimal dose for seasonal influenza vaccines in adult and elderly patients. METHODS: A total of 256 subjects, including adult (aged 18-60 years) and elderly (aged over 60 years) individuals, were enrolled. Subjects were randomly assigned in a 1:1:1:1 ratio to receive a whole-virion, aluminium-adjuvanted trivalent influenza vaccine containing 3.5, 6, 9 or 15 μg haemagglutinin of seasonal A/H1N1, A/H3N2 and B influenza antigens manufactured by Omninvest Ltd., Hungary. Serum antibody titres against the vaccine virus strains were measured by haemagglutination inhibition. RESULT: All vaccines were well tolerated. All four vaccines fulfilled all three immunogenicity licensing criteria, as determined by the European Committee for Proprietary Medicinal Products (CPMP)/Biotechnology Working Party (BWP)/214/96 guideline for all three virus strains and both age groups. The 3.5 μg vaccine showed 28% less seroconversion compared to the 15 μg dose in terms of influenza AH3N2 in the adult group (95% confidence interval -51, -3; P < 0.05). All other doses showed no significant difference in immunogenicity compared with the licensed vaccine containing 15 μg haemagglutinin. CONCLUSIONS: Our data suggested that significant dose sparing is possible with the use of whole-virion vaccines and aluminium adjuvants, without compromising safety. This could have significant economic and public health impacts.
RCT Entities:
AIMS: The currently licensed seasonal trivalent influenza vaccines contain 15 μg haemagglutinin per strain for adult, and up to 60 μg for elderly patients. However, due to recent shortages, dose sparing to increase production capacity would be highly desirable. In the present study, we attempted to find a dose-response relationship for immunogenicity and, thus, the optimal dose for seasonal influenza vaccines in adult and elderly patients. METHODS: A total of 256 subjects, including adult (aged 18-60 years) and elderly (aged over 60 years) individuals, were enrolled. Subjects were randomly assigned in a 1:1:1:1 ratio to receive a whole-virion, aluminium-adjuvanted trivalent influenza vaccine containing 3.5, 6, 9 or 15 μg haemagglutinin of seasonal A/H1N1, A/H3N2 and B influenza antigens manufactured by Omninvest Ltd., Hungary. Serum antibody titres against the vaccine virus strains were measured by haemagglutination inhibition. RESULT: All vaccines were well tolerated. All four vaccines fulfilled all three immunogenicity licensing criteria, as determined by the European Committee for Proprietary Medicinal Products (CPMP)/Biotechnology Working Party (BWP)/214/96 guideline for all three virus strains and both age groups. The 3.5 μg vaccine showed 28% less seroconversion compared to the 15 μg dose in terms of influenza AH3N2 in the adult group (95% confidence interval -51, -3; P < 0.05). All other doses showed no significant difference in immunogenicity compared with the licensed vaccine containing 15 μg haemagglutinin. CONCLUSIONS: Our data suggested that significant dose sparing is possible with the use of whole-virion vaccines and aluminium adjuvants, without compromising safety. This could have significant economic and public health impacts.
Authors: Robert B Belshe; Sharon E Frey; Irene L Graham; Edwin L Anderson; Lisa A Jackson; Paul Spearman; Srilatha Edupuganti; Mark J Mulligan; Nadine Rouphael; Patricia Winokur; Rowena J Dolor; Christopher W Woods; Emmanuel B Walter; Wilbur H Chen; Christine Turley; Kathryn M Edwards; C Buddy Creech; Heather Hill; Abbie R Bellamy Journal: JAMA Date: 2014-10-08 Impact factor: 56.272
Authors: Allison Kempe; Matthew F Daley; Shannon Stokley; Lori A Crane; Brenda L Beaty; Jennifer Barrow; Christine Babbel; L Miriam Dickinson; John F Steiner; Stephen Berman Journal: Am J Prev Med Date: 2007-12 Impact factor: 5.043
Authors: Felix Geeraedts; Nadege Goutagny; Veit Hornung; Martina Severa; Aalzen de Haan; Judith Pool; Jan Wilschut; Katherine A Fitzgerald; Anke Huckriede Journal: PLoS Pathog Date: 2008-08-29 Impact factor: 6.823
Authors: Stephen Ph Alexander; Eamonn Kelly; Neil Marrion; John A Peters; Helen E Benson; Elena Faccenda; Adam J Pawson; Joanna L Sharman; Christopher Southan; O Peter Buneman; William A Catterall; John A Cidlowski; Anthony P Davenport; Doriano Fabbro; Grace Fan; John C McGrath; Michael Spedding; Jamie A Davies Journal: Br J Pharmacol Date: 2015-12 Impact factor: 8.739
Authors: Maria Auladell; Xiaoxiao Jia; Luca Hensen; Brendon Chua; Annette Fox; Thi H O Nguyen; Peter C Doherty; Katherine Kedzierska Journal: Front Immunol Date: 2019-07-02 Impact factor: 7.561